Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review
Authors
Keywords
Non-small cell lung cancer, Cancer treatment, Cost-effectiveness analysis, Cancer immunotherapy, Chemotherapy, Systematic reviews, Health economics, Metastasis
Journal
PLoS One
Volume 15, Issue 9, Pages e0238536
Publisher
Public Library of Science (PLoS)
Online
2020-09-03
DOI
10.1371/journal.pone.0238536
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the 1st-line treatment of squamous NSCLC in the U.S.
- (2019) Ralph P Insinga et al. CURRENT MEDICAL RESEARCH AND OPINION
- Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review
- (2019) Natalia Ruiz-Negrón et al. PHARMACOECONOMICS
- Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
- (2019) Weiting Liao et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
- (2019) Umang Ondhia et al. JOURNAL OF MEDICAL ECONOMICS
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) D Planchard et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
- (2019) Alfredo Addeo et al. Frontiers in Oncology
- First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis
- (2019) XiaoMin Wan et al. CANCER
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
- (2019) Peter Paul Yu et al. Journal for ImmunoTherapy of Cancer
- Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores
- (2019) Kexun Zhou et al. LUNG CANCER
- Cost–effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA
- (2019) Min Huang et al. Immunotherapy
- Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
- (2019) Longjiang She et al. LUNG CANCER
- First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: a cost-effectiveness analysis from the UK health care perspective
- (2018) Xiaohan Hu et al. LUNG CANCER
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
- (2018) Mina Georgieva et al. LUNG CANCER
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
- (2018) Ralph P. Insinga et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France
- (2018) Christos Chouaid et al. LUNG CANCER
- Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System
- (2018) Steven D. Criss et al. JAMA Oncology
- A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
- (2018) Vivek Verma et al. Journal for ImmunoTherapy of Cancer
- Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models
- (2018) Lan Gao et al. Applied Health Economics and Health Policy
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
- (2017) Min Huang et al. PHARMACOECONOMICS
- Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies
- (2017) Sergio Iannazzo et al. PHARMACOECONOMICS
- A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing
- (2016) Klazien Matter-Walstra et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
- (2016) Min Huang et al. JOURNAL OF MEDICAL ECONOMICS
- Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes
- (2016) Ron Goeree et al. JOURNAL OF MEDICAL ECONOMICS
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
- (2013) Don Husereau et al. PHARMACOECONOMICS
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
- (2013) Don Husereau et al. VALUE IN HEALTH
- Projections of the Cost of Cancer Care in the United States: 2010-2020
- (2011) A. B. Mariotto et al. JNCI-Journal of the National Cancer Institute
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
- (2010) David Moher et al. International Journal of Surgery
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search